Daily Target 2X Long MRNA ETF
MRNX
New York Stock Exchange Arca24.04
USD
+2.77
- -
CIK
0001924868
ISIN
US88636X8157
CUSIP
88636X815
Return %
Stock
S&P500
1Y
17.98
19.25
3Y
17.98
65.11
5Y
17.98
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James Atkinson
- Sector
- Financial Services
- Industry
- Asset Management - Leveraged
- Address
- 234 West Florida Street Milwaukee NY United States of America 53204
- IPO Date
- Feb 4, 2026
- CIK
- 0001924868
- Website
- defianceetfs.com
- Similar Companies
- Business
- Defiance ETFs is an exchange-traded fund sponsor and registered investment advisor that issues a diverse lineup of thematic, leveraged single-stock, and income-generating ETFs targeting high-growth sectors such as technology, quantum computing, artificial intelligence, biotechnology, and commodities. The firm offers thematic products including the Defiance Quantum ETF (QTUM), Defiance Connective Technologies ETF (SIXG), Defiance AI & Power Infrastructure ETF (AIPO), and Defiance Drone and Modern Warfare ETF (JEDI); leveraged long ETFs such as the Daily Target 2X Long MSTR ETF (MSTX), Daily Target 2X Long SMCI ETF (SMCX), Daily Target 2X Long MRNA ETF (MRNX), and over 30 others providing 2X daily amplified exposure to individual stocks like IONQ, IREN, AVGO, and LLY; leveraged short ETFs including the Daily Target 2X Short PLTR ETF (PLTZ) and Daily Target 2X Short IONQ ETF (IONZ); and income ETFs like the Nasdaq 100 Weekly Distribution ETF (QQQY), S&P 500 Weekly Distribution ETF (WDTE), and Oil Enhanced Options Income ETF (USOY), which employ options strategies for targeted yields. Defiance ETFs primarily serves active traders, tactical investors, and those seeking leveraged or income-oriented exposure to innovative companies and trends, with products listed on U.S. exchanges and targeted at domestic markets. Founded in 2018 and headquartered in Miami, Florida, the company operates from the United States with a focus on North American investors, though it has initiated European expansion. In recent developments, Defiance ETFs launched the Defiance Daily Target 2X Long MRNA ETF (MRNX) on February 4, 2026, marking its entry into leveraged exposure for Moderna's mRNA biotechnology platform and expanding its single-stock lineup amid surging assets under management that surpassed $8 billion as of January 2026; the firm also introduced several new leveraged products in late 2025 and early 2026, such as the Daily Target 2X Long MRNA ETF (MRNX), Daily Target 2X Long ZETA ETF (ZETX), and Daily Target 2X Long RCAT ETF (RCAX), alongside the thematic Defiance Retail Kings ETF (RKNG) in January 2026; additionally, it announced a strategic partnership with HANetf in January 2026 to launch its first ETF in Europe, supporting international growth following robust adoption of flagship funds like QTUM, which exceeded $3.4 billion in assets.